Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2013

Open Access 01-12-2013 | Study protocol

Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial

Authors: Kerry-Ann F O’Grady, Keith Grimwood, Allan Cripps, Edward K Mulholland, Peter Morris, Paul J Torzillo, Nicholas Wood, Heidi Smith-Vaughan, Amber Revell, Andrew Wilson, Peter Van Asperen, Peter Richmond, Ruth Thornton, Sheree Rablin, Anne B Chang

Published in: Trials | Issue 1/2013

Login to get access

Abstract

Background

Recurrent protracted bacterial bronchitis (PBB), chronic suppurative lung disease (CSLD) and bronchiectasis are characterised by a chronic wet cough and are important causes of childhood respiratory morbidity globally. Haemophilus influenzae and Streptococcus pneumoniae are the most commonly associated pathogens. As respiratory exacerbations impair quality of life and may be associated with disease progression, we will determine if the novel 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) reduces exacerbations in these children.

Methods

A multi-centre, parallel group, double-blind, randomised controlled trial in tertiary paediatric centres from three Australian cities is planned. Two hundred six children aged 18 months to 14 years with recurrent PBB, CSLD or bronchiectasis will be randomised to receive either two doses of PHiD-CV or control meningococcal (ACYW135) conjugate vaccine 2 months apart and followed for 12 months after the second vaccine dose. Randomisation will be stratified by site, age (<6 years and ≥6 years) and aetiology (recurrent PBB or CSLD/bronchiectasis). Clinical histories, respiratory status (including spirometry in children aged ≥6 years), nasopharyngeal and saliva swabs, and serum will be collected at baseline and at 2, 3, 8 and 14 months post-enrolment. Local and systemic reactions will be recorded on daily diaries for 7 and 30 days, respectively, following each vaccine dose and serious adverse events monitored throughout the trial. Fortnightly, parental contact will help record respiratory exacerbations. The primary outcome is the incidence of respiratory exacerbations in the 12 months following the second vaccine dose. Secondary outcomes include: nasopharyngeal carriage of H. influenzae and S. pneumoniae vaccine and vaccine- related serotypes; systemic and mucosal immune responses to H. influenzae proteins and S. pneumoniae vaccine and vaccine-related serotypes; impact upon lung function in children aged ≥6 years; and vaccine safety.

Discussion

As H. influenzae is the most common bacterial pathogen associated with these chronic respiratory diseases in children, a novel pneumococcal conjugate vaccine that also impacts upon H. influenzae and helps prevent respiratory exacerbations would assist clinical management with potential short- and long-term health benefits. Our study will be the first to assess vaccine efficacy targeting H. influenzae in children with recurrent PBB, CSLD and bronchiectasis.

Trial registration

Australia and New Zealand Clinical Trials Registry (ANZCTR) number: ACTRN12612000034​831.
Appendix
Available only for authorised users
Literature
1.
Irwin RS, Baumann MH, Bolser DC, Boulet LP, Braman SS, Brightling CE, Brown KK, Canning BJ, Chang AB, Dicpinigaitis PV, Eccles R, Glomb WB, Goldstein LB, Graham LM, Hargreave FE, Kvale PA, Lewis SZ, McCool FD, McCrory DC, Prakash UB, Pratter MR, Rosen MJ, Schulman E, Shannon JJ, Smith Hammond C, Tarlo SM, American College of Chest Physicians (ACCP): Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest. 2006, 129 (1 Suppl): 1S-23S.CrossRefPubMedPubMedCentral
2.
Britt H, Miller GC, Charles J, Henderson J, Bayram C, Pan Y, Valenti L, Harrison C, O’Halloran J, Fahridin S: General Practice Activity in Australia 2009–10. General Practice Series No. 27. 2010, AIHW: Canberra
3.
Chang AB, Glomb WB: Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines. Chest. 2006, 129 (1 Suppl): 260S-283S.CrossRefPubMed
4.
Marchant JM, Newcombe PA, Juniper EF, Sheffield JK, Stathis SL, Chang AB: What is the burden of chronic cough for families?. Chest. 2008, 134: 303-309.CrossRefPubMed
5.
Field CE: Bronchiectasis in childhood; aetiology and pathogenesis, including a survey of 272 cases of doubtful irreversible bronchiectasis. Pediatrics. 1949, 4: 231-248.PubMed
6.
Cole PJ: Inflammation: a two-edged sword - the model of bronchiectasis. Eur J Respir Dis Suppl. 1986, 147: 6-15.PubMed
7.
Chang AB, Robertson CF, Van Asperen PP, Glasgow NJ, Mellis CM, Masters IB, Teoh L, Tjhung I, Morris PS, Petsky HL, Willis C, Landau LI: A multicenter study on chronic cough in children: burden and etiologies based on a standardized management pathway. Chest. 2012, 142: 943-950.CrossRefPubMed
8.
Craven V, Everard ML: Protracted bacterial bronchitis: reinventing an old disease. Arch Dis Child. 2012, 98: 72-76.CrossRefPubMed
9.
Marchant J, Masters IB, Champion A, Petsky H, Chang AB: Randomised controlled trial of amoxycillin clavulanate in children with chronic wet cough. Thorax. 2012, 67: 689-693.CrossRefPubMed
10.
Chang AB, Redding GJ, Everard ML: Chronic wet cough: protracted bronchitis, chronic suppurative lung disease and bronchiectasis. Pediatr Pulmonol. 2008, 43: 519-531.CrossRefPubMed
11.
Chang AB, Bell SC, Byrnes CA, Grimwood K, Holmes PW, King PT, Kolbe J, Landau LI, Maguire GP, McDonald MI, Reid DW, Thien FC, Torzillo PJ: Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust. 2010, 193: 356-365.PubMed
12.
Kapur N, Karadag B: Differences and similarities in non-cystic fibrosis bronchiectasis between developing and affluent countries. Paediatr Respir Rev. 2011, 12: 91-96.CrossRefPubMed
13.
Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT: Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012, 186: 657-665.CrossRefPubMed
14.
King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW: Microbiologic follow-up study in adult bronchiectasis. Respir Med. 2007, 101: 1633-1638.CrossRefPubMed
15.
Bandi V, Apicella MA, Mason E, Murphy TF, Siddiqi A, Atmar RL, Greenberg SB: Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med. 2001, 164: 2114-2119.CrossRefPubMed
16.
Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA: Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med. 2000, 109: 288-295.CrossRefPubMed
17.
Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA: Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002, 57: 759-764.CrossRefPubMedPubMedCentral
18.
Zgherea D, Pagala S, Mendiratta M, Marcus MG, Shelov SP, Kazachkov M: Bronchoscopic findings in children with chronic wet cough. Pediatrics. 2012, 129: e364-e369.CrossRefPubMed
19.
Grimwood K: Airway microbiology and host defences in paediatric non-CF bronchiectasis. Paediatr Respir Rev. 2011, 12: 111-118.CrossRefPubMed
20.
Sethi S, Murphy TF: Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008, 359: 2355-2366.CrossRefPubMed
21.
Sethi S, Wrona C, Eschberger K, Lobbins P, Cai X, Murphy TF: Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008, 177: 491-497.CrossRefPubMed
22.
Kapur N, Masters IB, Newcombe P, Chang AB: The burden of disease in pediatric non-cystic fibrosis bronchiectasis. Chest. 2012, 141: 1018-1024.CrossRefPubMed
23.
Murray MP, Turnbull K, MacQuarrie S, Pentland JL, Hill AT: Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J. 2009, 34: 125-131.CrossRefPubMed
24.
Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, Román-Sánchez P, Soriano J: Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007, 132: 1565-1572.CrossRefPubMed
25.
Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, Wilson R: Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J. 2009, 34: 843-849.CrossRefPubMed
26.
Kapur N, Masters IB, Chang AB: Exacerbations in noncystic fibrosis bronchiectasis: Clinical features and investigations. Respir Med. 2009, 103: 1681-1687.CrossRefPubMed
27.
Borrow R, Heath PT, Siegrist CA: Use of pneumococcal polysaccharide vaccine in children: what is the evidence?. Curr Opin Infect Dis. 2012, 25: 292-303.CrossRefPubMed
28.
Foxwell AR, Cripps AW, Dear KB: Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Cochrane Database Syst Rev. 2006, 4: CD001958
29.
Forsgren A, Riesbeck K, Janson H: Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clin Infect Dis. 2008, 46: 726-731.CrossRefPubMed
30.
Khan MN, Kaur R, Pichichero ME: Bactericidal antibody response against P6, protein D, and OMP26 of nontypeable Haemophilus influenzae after acute otitis media in otitis-prone children. FEMS Immunol Med Microbiol. 2012, 65: 439-447.CrossRefPubMed
31.
Sharma SK, Roumanes D, Almudevar A, Mosmann TR, Pichichero ME: CD4(+) T-cell responses among adults and young children in response to Streptococcus pneumoniae and Haemophilus influenzae vaccine candidate protein antigens. Vaccine. 2013, 31: 3090-3097.CrossRefPubMedPubMedCentral
32.
Poolman JT, Bakaletz L, Cripps A, Denoel PA, Forsgren A, Kyd J, Lobet Y: Developing a nontypeable Haemophilus influenzae (NTHi) vaccine. Vaccine. 2000, 19 (Suppl 1): S108-S115.CrossRefPubMed
33.
Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, Schuerman L: Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet. 2006, 367: 740-748.CrossRefPubMed
34.
van den Bergh MR, Spijkerman J, Swinnen KM, François NA, Pascal TG, Borys D, Schuerman L, Ijzerman EP, Bruin JP, van der Ende A, Veenhoven RH, Sanders EA: Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis. 2013, 56: e30-e39.CrossRefPubMed
35.
GlaxoSmithKline: COMPAS: A phase III study to demonstrate efficacy of GSK Biologicals’ 10-valent pneumococcal vaccine (GSK1024850A) against Community Acquired Pneumonia and Acute Otitis Media. Protocol ID 109563_1. Secondary COMPAS: A phase III study to demonstrate efficacy of GSK Biologicals’ 10-valent pneumococcal vaccine (GSK1024850A) against Community Acquired Pneumonia and Acute Otitis Media. Protocol ID 109563_1 2013. [http://​www.​gsk-clinicalstudyreg​ister.​com]
36.
O’Brien KL, Nohynek H, World Health Organization Pneumococcal Vaccine Trials Carriage Working Group: Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J. 2003, 22: 133-140.PubMed
37.
Leach AJ, Stubbs E, Hare K, Beissbarth J, Morris PS: Comparison of nasal swabs with nose blowing for community-based pneumococcal surveillance of healthy children. J Clin Microbiol. 2008, 46: 2081-2082.CrossRefPubMedPubMedCentral
38.
Hare KM, Grimwood K, Leach AJ, Smith-Vaughan H, Torzillo PJ, Morris PS, Chang AB: Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian indigenous children with bronchiectasis. J Pediatr. 2010, 157: 1001-1005.CrossRefPubMed
39.
Hare KM, Binks MJ, Grimwood K, Chang AB, Leach AJ, Smith-Vaughan H: Culture and PCR detection of Haemophilus influenzae and Haemophilus haemolyticus in Australian Indigenous children with bronchiectasis. J Clin Microbiol. 2012, 50: 2444-2445.CrossRefPubMedPubMedCentral
40.
Werno AM, Anderson TP, Murdoch DR: Association between pneumococcal load and disease severity in adults with pneumonia. J Med Microbiol. 2012, 61: 1129-1135.CrossRefPubMed
41.
Lal G, Balmer P, Stanford E, Martin S, Warrington R, Borrow R: Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J Immunol Methods. 2005, 296: 135-147.CrossRefPubMed
42.
Menon VJ, Corscadden KJ, Fuery A, Thornton RB, Kirkham LA, Richmond PC, Wiertsema SP: Children with otitis media mount a pneumococcal serotype specific serum IgG and IgA response comparable to healthy controls after pneumococcal conjugate vaccination. Vaccine. 2012, 30: 3136-3144.CrossRefPubMed
43.
44.
Fleming TR, Harrington DP, O’Brien PC: Designs for group sequential tests. Control Clin Trials. 1984, 5: 348-361.CrossRefPubMed
45.
Kramar A, Bascoul-Mollevi C: Early stopping rules in clinical trials based on sequential monitoring of serious adverse events. Med Decis Making. 2009, 29: 343-350.CrossRefPubMed
46.
Bastardo CM, Sonnappa S, Stanojevic S, Navarro A, Lopez PM, Jaffe A, Bush A: Non-cystic fibrosis bronchiectasis in childhood: longitudinal growth and lung function. Thorax. 2009, 64: 246-251.CrossRefPubMed
47.
Kapur N, Masters IB, Chang AB: Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis: what influences lung function stability?. Chest. 2010, 138: 158-164.CrossRefPubMed
48.
Kaur R, Casey JR, Pichichero ME: Serum antibody response to three non-typeable Haemophilus influenzae outer membrane proteins during acute otitis media and nasopharyngeal colonization in otitis prone and non-otitis prone children. Vaccine. 2011, 29: 1023-1028.CrossRefPubMed
49.
Sharma SK, Casey JR, Pichichero ME: Reduced memory CD4+ T-cell generation in the circulation of young children may contribute to the otitis-prone condition. J Infect Dis. 2011, 204: 645-653.CrossRefPubMedPubMedCentral
50.
Russell FM, Carapetis JR, Balloch A, Licciardi PV, Jenney AW, Tikoduadua L, Waqatakirewa L, Pryor J, Nelson J, Byrnes GB, Cheung YB, Tang ML, Mulholland EK: Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine. 2010, 28: 3341-3349.CrossRefPubMedPubMedCentral
51.
Dagan R, Givon-Lavi N, Greenberg D, Fritzell B, Siegrist CA: Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis. 2010, 201: 1570-1579.CrossRefPubMed
52.
Vakevainen M, Soininen A, Lucero M, Nohynek H, Auranen K, Mäkelä PH, Williams G, Käyhty H, ARIVAC Consortium: Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination. J Pediatr. 2010, 157: 778-783.CrossRefPubMed
53.
Priftis KN, Litt D, Manglani S, Anthracopoulos MB, Thickett K, Tzanakaki G, Fenton P, Syrogiannopoulos GA, Vogiatzi A, Douros K, Slack M, Everard ML: Bacterial bronchitis caused by Streptococcus pneumoniae and non-typable Haemophilus influenzae in children: the impact of vaccination. Chest. 2013, 143: 152-157.CrossRefPubMed
54.
O’Grady KA, Lee KJ, Carlin JB, Torzillo PJ, Chang AB, Mulholland EK, Lambert SB, Andrews RM: Increased risk of hospitalization for acute lower respiratory tract infection among Australian indigenous infants 5–23 months of age following pneumococcal vaccination: a cohort study. Clin Infect Dis. 2010, 50: 970-978.CrossRefPubMed
55.
Hare KM, Leach AJ, Morris PS, Smith-Vaughan H, Torzillo P, Bauert P, Cheng AC, McDonald MI, Brown N, Chang AB, Grimwood K: Impact of recent antibiotics on nasopharyngeal carriage and lower airway infection in Indigenous Australian children with non-cystic fibrosis bronchiectasis. Int J Antimicrob Agents. 2012, 40: 365-369.CrossRefPubMed
56.
Hawdon N, Biman B, McCready W, Brigden M, Malik S, Vergidis D, Kisselgoff O, Ulanova M: Antibody against Haemophilus influenzae protein D in patients with chronic conditions causing secondary immunodeficiency. Vaccine. 2012, 30: 1235-1238.CrossRefPubMed
57.
Leach AJ, Boswell JB, Asche V, Nienhuys TG, Mathews JD: Bacterial colonization of the nasopharynx predicts very early onset and persistence of otitis media in Australian aboriginal infants. Pediatr Infect Dis J. 1994, 13: 983-989.CrossRefPubMed
58.
O’Grady KA, Torzillo PJ, Chang AB: Hospitalisation of Indigenous children in the Northern Territory for lower respiratory illness in the first year of life. Med J Aust. 2010, 192: 586-590.PubMed
59.
Prymula R, Habib A, Francois N, Borys D, Schuerman L: Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol. Vaccine. 2013, 31: 2080-2088.CrossRefPubMed
60.
Prymula R, Hanovcova I, Splino M, Kriz P, Motlova J, Lebedova V, Lommel P, Kaliskova E, Pascal T, Borys D, Schuerman L: Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vaccine. 2011, 29: 1959-1967.CrossRefPubMed
61.
Spijkerman J, Prevaes SM, van Gils EJ, Veenhoven RH, Bruin JP, Bogaert D, Wijmenga-Monsuur AJ, van den Dobbelsteen GP, Sanders EA: Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis. PLoS One. 2012, 7: e39730-Erratum in: PLoS One 2012, 7CrossRefPubMedPubMedCentral
62.
63.
Therapeutic Goods Administration: Note for Guidance on Good Clinical Practice (CMP/ICH/135/95). 2000, Canberra: Australian Government Department of Health and Ageing
64.
Mulholland EK: Use of vaccine trials to estimate burden of disease. J Health Popul Nutr. 2004, 22: 257-PubMed
Metadata
Title
Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial
Authors
Kerry-Ann F O’Grady
Keith Grimwood
Allan Cripps
Edward K Mulholland
Peter Morris
Paul J Torzillo
Nicholas Wood
Heidi Smith-Vaughan
Amber Revell
Andrew Wilson
Peter Van Asperen
Peter Richmond
Ruth Thornton
Sheree Rablin
Anne B Chang
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Trials / Issue 1/2013
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-14-282

Other articles of this Issue 1/2013

Trials 1/2013 Go to the issue

Study protocol

International subarachnoid aneurysm trial – ISAT Part II: Study protocol for a randomized controlled trial

Study protocol

Cardiovascular disease risk reduction in rural China: a clustered randomized controlled trial in Zhejiang

Study protocol

The group-based social skills training SOSTA-FRA in children and adolescents with high functioning autism spectrum disorder - study protocol of the randomised, multi-centre controlled SOSTA - net trial

Study protocol

Predictive risk stratification model: a progressive cluster-randomised trial in chronic conditions management (PRISMATIC) research protocol

Study protocol

Effectiveness of a tailored intervention to improve cardiovascular risk management in primary care: study protocol for a randomised controlled trial

Study protocol

An open-label study of effects of acupuncture on chronic fatigue syndrome and idiopathic chronic fatigue: study protocol for a randomized controlled trial